KIF11 and cancer: Inhibitors of the kinesin-5 (also known as Eg5 and KIF11), a mitotic kinesin, are promising candidates for GBM therapy but can be rendered ineffective due to various mechanisms of resistance.16 Kinesin-5 is a microtubule-associated motor protein that organizes the bipolar mitotic spindle and facilitates cell migration.17,18 Its involvement in two hallmarks of cancer, proliferation and invasion, makes it a potential therapeutic target.